NCT02731586 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Haniffa MA, Collin MP, Buckley CD, Dazzi F
Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica. 2009 Feb;94(2):258-63. doi: 10.3324/haematol.13699. Epub 2008 Dec 23. Review.
Lavenus S, Berreur M, Trichet V, Pilet P, Louarn G, Layrolle P
Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. Eur Cell Mater. 2011 Aug 26;22:84-96; discussion 96.
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003 Oct;31(10):890-6.
Limet R
Advantages of side-to-side anastomosis in coronary surgery[(author's transl)]. Acta Chir Belg. 1976 Jul;75(4):390-401. French.
Meredith N
Assessment of implant stability as a prognostic determinant. Int J Prosthodont. 1998 Sep-Oct;11(5):491-501. Review.
Uccelli A, Moretta L, Pistoia V
Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008 Sep;8(9):726-36. doi: 10.1038/nri2395. Review.

Comparative Clinical Evaluation of Osseointegration of Dental Implants Placed With and Without, the Use of Dental Pulp-derived Allogenic Mesenchymal Stem Cells.

Details for clinical trial NCT02731586

Clinical trial NCT02731586 - References